Israeli Biological Institute Develops Coronavirus Antibody, Defence Minister Says

Henrietta Strickland
May 5, 2020

According to a statement by the defence ministry, Israel Institute for Biological Research (IIBR) has completed the development phase of COVID-19 antibody or passive vaccine.

Israeli scientists have made a significant breakthrough in the fight on the Coronavirus (COVID-19) pandemic and have developed a potent antibody that attacks the virus.

The statement said the antibody's development had been completed.

IIBR is now working to patent its antibody and secure a contract for its commercial development.

Defense Minister Naftali Bennett said on Monday that I am proud of the staff of the Biological Institute, which has achieved a great success. "The Jewish creativity and ingenuity brought about this incredible achievement".

Shapira noted that there has been "significant progress" in planning for the vaccine and added that preparations are now being made ahead of a model for the start of experimentation on animals, a crucial stage before trials on humans are carried out.

There have been protests from desperate business owners demanding that Prime Minister Benjamin Netanyahu allow the open-air markets to operate once again.

Numerous research teams all over the world are participating in the race to develop a vaccine for COVID-19. But so far there's no way to predict which - if any - vaccine will work safely, or even to name a front-runner. Some estimates suggest that a vaccine could be tested and distributed globally in as little as 12 months.

Even if a first useful vaccine is identified, there won't be enough for everyone initially.

According to foreign media reports, the IIBR is involved in developing chemical and biological weapons and antidotes and defences against them.

In March, Israeli day by day Ha'aretz, quoting medical sources, had reported that scientists on the institute had made a major breakthrough in understanding the organic mechanism and qualities of the virus, together with higher diagnostic functionality, manufacturing of antibodies for individuals who have already got the virus and growth of a vaccine.

Other reports by Click Lancashire

Discuss This Article